The NPPA has revised prices for 137 non-scheduled anti-cancer drugs after capping trade margins at 30 per cent. Effective November 9, the measure is expected to reduce prices by up to 70 per cent and ease treatment costs.
The MRP rates on the drug indicated were significantly higher than the ceiling price fixed for the product under the Drugs (Prices Control) Order, 2013 by National Pharmaceutical Pricing Authority (c), the price control regulatory authority
The DCA seized stocks of Supralax Syrup (Sodium Picosulfate Oral Solution BP) manufactured by Shervotec Pharmaceuticals, Solan, Himachal Pradesh and marketed by MABO Pharmacls, Chennai from a medical shop at Karimnagar.
